Neurotoxin Mechanisms and Processes Relevant to Parkinson's Disease: An Update

被引:51
|
作者
Segura-Aguilar, Juan [1 ]
Kostrzewa, Richard M. [2 ]
机构
[1] Univ Chile, Fac Med, Mol & Clin Pharmacol, ICBM, Santiago 7, Chile
[2] E Tennessee State Univ, James H Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA
关键词
Parkinson's disease; 6-Hydroxydopamine; MPP+; MPTP; Ortho-quinones; Reactive oxygen species; Rotenone; NEURONAL CELL-DEATH; MPTP MOUSE MODEL; PROTECTS DOPAMINERGIC-NEURONS; ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; NEUROBLASTOMA SH-SY5Y CELLS; MITOCHONDRIAL COMPLEX-I; MPP+-INDUCED APOPTOSIS; PPAR-GAMMA AGONIST; 6-HYDROXYDOPAMINE-INDUCED OXIDATIVE STRESS;
D O I
10.1007/s12640-015-9519-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The molecular mechanism responsible for degenerative process in the nigrostriatal dopaminergic system in Parkinson's disease (PD) remains unknown. One major advance in this field has been the discovery of several genes associated to familial PD, including alpha synuclein, parkin, LRRK2, etc., thereby providing important insight toward basic research approaches. There is an consensus in neurodegenerative research that mitochon dria dysfunction, protein degradation dysfunction, aggregation of alpha synuclein to neurotoxic oligomers, oxidative and endoplasmic reticulum stress, and neuroinflammation are involved in degeneration of the neuromelanin-containing dopaminergic neurons that are lost in the disease. An update of the mechanisms relating to neurotoxins that are used to produce preclinical models of ParkinsonA ' s disease is presented. 6-Hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and rotenone have been the most wisely used neurotoxins to delve into mechanisms involved in the loss of dopaminergic neurons containing neuromelanin. Neurotoxins generated from dopamine oxidation during neuromelanin formation are likewise reviewed, as this pathway replicates neurotoxin-induced cellular oxidative stress, inactivation of key proteins related to mitochondria and protein degradation dysfunction, and formation of neurotoxic aggregates of alpha synuclein. This survey of neurotoxin modeling-highlighting newer technologies and implicating a variety of processes and pathways related to mechanisms attending PD-is focused on research studies from 2012 to 2014.
引用
收藏
页码:328 / 354
页数:27
相关论文
共 50 条
  • [41] Parkinson's Disease: Update on Medication Management
    Kriebel-Gasparro, Ann
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2016, 12 (03): : E81 - E89
  • [42] Behavioral addictions in Parkinson's disease: An update
    Razzolini, Lorenzo
    Grassi, Giacomo
    Albani, Giovanni
    JOURNAL OF BEHAVIORAL ADDICTIONS, 2024, 13 : 32 - 33
  • [43] An Update on Gene Therapy in Parkinson's Disease
    Witt, Jennifer
    Marks, William J., Jr.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (04) : 362 - 370
  • [44] Update on the diagnosis and management of Parkinson's disease
    Kobylecki, Christopher
    CLINICAL MEDICINE, 2020, 20 (04) : 393 - 398
  • [45] Pregnancy and Parkinson's disease: A review and update
    Seier, M.
    Hiller, A.
    MOVEMENT DISORDERS, 2017, 32
  • [46] Probiotics and the Treatment of Parkinson's Disease: An Update
    Mirzaei, Hamed
    Sedighi, Saman
    Kouchaki, Ebrahim
    Barati, Erfaneh
    Dadgostar, Ehsan
    Aschner, Michael
    Tamtaji, Omid Reza
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2022, 42 (08) : 2449 - 2457
  • [47] Pathophysiology of Parkinson's disease: an update DISCUSSION
    Benabid, M. Alim-Louis
    Hauw, M. Jean-Jacques
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2010, 194 (07): : 1331 - 1332
  • [48] Regenerative Therapies for Parkinson’s Disease: An Update
    Thomas B. Stoker
    Roger A. Barker
    BioDrugs, 2018, 32 : 357 - 366
  • [49] Zonisamide in Parkinson's disease: a current update
    Goel, Atul
    Sugumaran, Ramkumar
    Narayan, Sunil K.
    NEUROLOGICAL SCIENCES, 2021, 42 (10) : 4123 - 4129
  • [50] Rasagiline for the treatment of Parkinson's disease: an update
    Stocchi, Fabrizio
    Fossati, Chiara
    Torti, Margherita
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (14) : 2231 - 2241